Introduction
African-Americans have a disproportionate elevation in chronic inflammation (1) after accounting for differences in BMI and other potential confounding factors. 
Materials and Methods

Study Design
This is a prospective, randomized, double-blind, placebo-controlled clinical trial of oral cholecalciferol (vitamin D3) in a community-based healthy black population (ClinicalTrials.gov NCT00585637). The protocol has been described in detail elsewhere Institute. All procedures were followed in accordance with institutional guidelines. 6 permission from their primary care doctors. A total of 328 individuals were enrolled into the parent trial ( Figure 1 ). Exclusion criteria included pregnancy, renal disease, preexisting parathyroid, thyroid, or calcium metabolism disorders, sarcoidosis, requirement for calcium channel blockers, type I diabetes, and active malignancies (other than nonmelanoma skin cancer). Those taking vitamin D supplementation were enrolled if they agreed to discontinue these medications for 6 months prior to enrollment and during the study.
Treatment
Participants were randomly assigned to 4 treatment arms: placebo; 1,000 IU; 2,000 IU; or 4,000 IU/day (Pharmavite LLC, Mission Hill, CA) of vitamin D 3 for 3 months. All capsules also contained 200 mg of calcium carbonate. All capsules were indistinguishable, and both participants and research staff were blinded to treatment assignment. Study medications were started in early winter (November or December) and were taken orally once daily for 3 months (completed in February or March).
End Points and Follow-up
The primary end points of the study were the changes in plasma inflammatory marker levels, IL-6, IL-10, sTNF-R2, and CRP, from baseline to the initial 3-month follow-up at the conclusion of supplement administration. Inflammatory markers also were measured at the 6-month follow-up. Individuals attended study visits at baseline, 3 months (at the end of randomized treatment), and 6 months (3 months after treatment discontinuation).
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Compliance and Safety
All participants were assessed for adverse events by study staff over the phone at week 2 of each month and in-person at the beginning of each month when the next month's supply of vitamins was provided. Participants were educated on the warning signs and symptoms of hypercalcemia. Any subject found to have serum calcium >10.5 mg/dL was immediately discontinued from the study and the PCP was notified.
Plasma Vitamin D Levels
Blood samples collected at baseline, 3, and 6 months were separated and plasma The levels of CRP were determined by means of a highly sensitive immunoturbidimetric assay with the use of reagents and calibrators from Denka Seiken; this assay has a day-to-day variability of 1 to 2 percent. Levels of sTNF-R2, and IL-6 and IL-10 were measured by means of enzyme-linked immunosorbent assays (R&D Systems), which have a day-to-day variability of 3.5 to 9.0 percent. Levels of sTNF-R2
show a strong correlation with TNF-α mRNA expression in human adipose tissue. (8) .
The mean intra-assay coefficients of variations from blinded quality control samples for each analyte were as follows: CRP, 2.6%; IL-6, 3.8%; IL-10, 10.3%; and sTNFR-2, 3.3%.
Statistical Analysis
The trial was designed with a statistical power of 80% to detect differences in plasma 25(OH)D level of 5.3 ng/mL between treatment groups. Based on this planned sample size, we estimated that the trial would have 80% power to detect a 25% change in inflammatory biomarkers IL-6, IL-10, sTNF-R2, and CRP per 1000 IU/d of vitamin D3.
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Baseline characteristics of the study population were compared between supplementation arms using the Chi-Square test for categorical variables and the Kruskal-Wallis test for continuous variables.
The primary end points of the study were the changes in plasma inflammatory marker levels, IL-6, IL-10, sTNF-R2, and CRP, from baseline to the initial 3-month follow-up.. For our primary analysis, we used linear regression with the dose of vitamin 
Results
Subject Characteristics According to Supplementation Arm
Among the 328 eligible participants, baseline characteristics were relatively well balanced with an overall median age of 51.0 and a median BMI of 31.0 kg/m 2 ( Table 1) .
Slightly more participants in the placebo and 1,000 IU/day arms had a past history of cancer than those assigned to 2,000 or 4,000 IU/day. Otherwise, there were no significant differences in any of the subject characteristics between the supplementation arms. The compliance rate with study medication in the entire cohort was 96.6%. 
Baseline Inflammatory Marker Predictors
At baseline, obese participants (BMI>30 kg/m 2 ) had significantly higher proinflammatory marker levels IL-6, sTNF-R2, and CRP than non-obese participants (Table 2) . We also assessed the influence of smoking history on baseline circulating inflammatory markers, IL-6, IL-10, sTNF-R2, and CRP. Current smokers had higher CRP levels than nonsmokers although the finding did not reach the level of statistical significance (p>0.05).
Finally, we assessed the relation between baseline inflammatory markers, IL-6, IL-10, sTNF-R2, and CRP and baseline plasma 25(OH)D levels. We stratified participants by 25(OH)D <20 ng/ml and 25(OH)D >20 ng/ml (Table 2) . No difference in baseline inflammatory markers was noted between the two groups except that participants with 25(OH)D <20 ng/ml had a statistically significant higher CRP level (P <.0001; Table 2 ). Even in models adjusted for BMI as a continuous variable, participants with 25(OH)D <20 ng/ml had a statistically significant higher CRP level ( P <.0001; Table 3 ).
Response to Vitamin D3 Supplementation by Treatment Arm
The primary end point of the study was change in plasma inflammatory marker level from baseline to the 3-month follow-up according to treatment arms. Overall, there was no statistically significant change in circulating levels of IL-6, IL-10, sTNF-R2, and Circulating 25(OH)D levels at 3 months differed significantly by vitamin D3 supplementation arm, with a median of 13.7, 29.7, 34.8, and 45.9 ng/mL for the placebo, 1,000 IU/day, 2,000 IU/day, and 4,000 IU/day arms, respectively (P =0.001). Notably, plasma 25(OH)D decreased at 3 months among participants treated with placebo (Table   3) .
Interaction analyses
Interaction analyses were performed to determine the treatment effects of vitamin 
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To our knowledge this is the largest randomized placebo controlled trial to Strengths of our study include its prospective design, the use of a double-blind controlled intervention, the broad set of inflammatory markers that were evaluated, and the collection of cytokine data in community dwelling adults. Moreover, the precision of inflammatory marker measurement appeared adequate with low coefficients of variation for each marker: CRP, 2.6%; IL-6, 3.8%; IL-10, 10.3%; and sTNFR-2, 3.3%.
Some limitations should also be considered. Given the 3-month duration of vitamin D supplementation, the end point of the study was not long-term benefit of supplementation on inflammation. In this heterogeneous convenience sample of healthy 
